Attached files
| file | filename |
|---|---|
| EX-99.1 - Isoray, Inc. | v188853_ex99-1.htm |
| EX-10.59 - Isoray, Inc. | v188853_ex10-59.htm |
United
States Securities And Exchange Commission
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported): June 23, 2010
(June 21,
2010)
ISORAY,
INC.
(Exact
name of registrant as specified in its charter)
|
Minnesota
(State
or other jurisdiction
of
incorporation)
|
001-33407
(Commission
File
Number)
|
41-1458152
(IRS
Employer
Identification
No.)
|
350 Hills Street, Suite 106,
Richland, Washington 99354
(Address
of principal executive offices) (Zip Code)
(509)
375-1202
(Registrant's
telephone number)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM
1.01 Entry into a Material Definitive Agreement
On June
21, 2010, IsoRay Medical, Inc. ("Medical"), a wholly owned subsidiary of IsoRay,
Inc. (the "Registrant"), entered into a License Agreement (the "Agreement") with
Hologic Inc. ("Hologic"). Under the Agreement, Medical received an
exclusive worldwide license to Hologic's Gliasite Radiation Therapy System for
intracavity radiation therapy of the brain. The Agreement is terminable
upon 90 days prior written notice by Medical or by either party following breach
of the Agreement and a 30 day notice and cure period.
On June
23, 2010, the Registrant issued a press release announcing its entry into the
Agreement, the text of which is attached hereto as Exhibit 99.1.
ITEM
9.01 Exhibits
|
|
(c)
|
Exhibits
|
|
10.59
|
License
Agreement, dated effective June 14, 2010, by and between IsoRay Medical,
Inc. and Hologic Inc. (confidential treatment requested for redacted
portions)
|
|
|
99.1
|
Press
release, dated June 23, 2010
|
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: June
23, 2010
|
IsoRay,
Inc., a Minnesota corporation
|
|||
|
By:
|
/s/ Dwight
Babcock
|
||
|
Dwight
Babcock, CEO
|
|||